Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-02-21

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Rhodes Pharmaceuticals L.P.)

View source ↗

Summary

The FDA approved a supplemental application for a generic buprenorphine/naloxone product from Rhodes Pharmaceuticals L.P. The approval confirms market authoriza…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)